BoB

Winners Phase 2 - 2017

Phase 2 - and the final winners!​​​​​​​​

On November 22nd the winners of BoB 2017 have been announced at the festive award ceremony in Vienna. ​​​​​​​​

30 projects have been submitted at phase 2 of the competition. The 10 best teams did receive individual businessplan- and presentation coaching. Each team had the opportunity to convice the jury of their business concept.​​​​​​​​

In the end the winning teams were:​​​​​​​​

1st prize winner sponsored by Shire: BHS Technology ​​​​​​​

BHS was found in February 2017 to develop a disruptive medical device, which will enhance the performance of microsurgical procedures for all participants - patient, surgeon and hospital.  After a successful demonstration of the concept, the team has started to develop the product for clinical use.​​​​​​​​

2nd prize winner sponsored by Roche Diagnostics and Roche Austria: MacroArray Diagnostics​​​​​​​​​​

Allergies and asthma affect one at least a quarter of the population. While often harmless, an increasing number of people suffer from severe allergies, resulting in more than 30.000 avoidable deaths per year.  Presently, there is no cost-efficient technology to improve the quality of diagnosis to an optimal level for patient-tailored and evidence based treatment.  The consequences of technology lagging knowledge are: generally elevated disease management costs, reduced quality of life and avoidable deaths.  We develop a multi-parameter allergy test covering close to 100% of the globally relevant allergens in a single lab test. ​​​​​​​

3rd prize winner sponsored by Boehringer Ingelheim: ImageBiopsy Lab​​​​​​​​

The objective of ImageBiopsy Lab (IB Lab GmbH) is to provide the tools for an effective treatment of knee-osteoarthritis. So far, osteoarthritis progression is considered to be hardly stoppable. Our software solution will change this.  IB Lab simplifies and accelerates the assessment, follow-up and prediction of knee osteoarthritis. Different stages of osteoarthritis and their accompanying symptoms are thus measured objectively and with minimal effort. An early prediction is possible for the first time without additional imaging efforts. The time-to-result is reduced from up to 3 minutes to a few seconds.   This means a significant relief for the medical professional in the daily routine. In addition, clearly defined treatment paths can be initiated on the basis of objectively measured parameters, resulting in an effective treatment of osteoarthritis progression.​​​​​​​

Medtech Award winner sponsored by LISAVienna: MorphoMed

MorphoMed GmbH (founded 2.5.2017) is a Vienna-based medical technology start-up company, specializing in the development and commercialization of Class III medical products for regenerating endogenous natural tissue (e.g. ligaments or tendons) using proprietary protected medical silk manufacturing technology. MorphoMed wants to become a sustainable player in the field of regenerative, silk based medicine.   The company's lead product is an anterior cruciate ligament made of medical silk (RegACL - "regenerative anterior cruciate ligament"), which has already been successfully tested in studies with large animals (sheep). The development, production, clinical approval, product launch and sales of RegACL will form the technological and commercial basis for building up MorphoMed GmbH and for the development of derived and related silk products.  Before becoming cash positive in 2021, financing of EUR 2,9 Million is needed from private equity, public grants and strategic cooperation partners. Commercial success will be driven by the development and market introduction of the lead product RegACL but also by a strong pipeline of related products based on the silk manufacturing technology.​​​​​​

More impressions on the final award ceremony can be found here!




Fußzeile: